The detection of illicit drugs in oral fluid: Another potential strategy to reduce illicit drug-related harm

Drug and Alcohol Review

Volumn 27, Issue 1, 2008, Pages 99-107

  Dyer, Kyle R ^a,b,c   Wilkinson, Catherine ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b Drug and Alcohol Office   (Australia)

^c Perth Radiological Clinic   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

STREET DRUG;

ADDICTION; ARTICLE; AUSTRALIA; CHEMISTRY; HARM REDUCTION; HUMAN; METHODOLOGY; SALIVA; SUBSTANCE ABUSE;

AUSTRALIA; HARM REDUCTION; HUMANS; SALIVA; STREET DRUGS; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS;

EID: 36549048805     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1080/09595230701727583     Document Type: Article

References (66)

1. Bale RN. Outcome research in therapeutic communities for drug abusers: a critical review 1963-1975. Int J Addict 1979;14:1053-74.
2. Rouen D, Dolan K. Supporting needle and syringe programs in Australia. Aust NZ J Public Health 2001;25:187.
3. Cone EJ. Saliva testing for drugs of abuse. Ann NY Acad Sei 1993;694:91-127.
4. Wolff K, Strang J. Therapeutic drug monitoring for methadone: scanning the horizon [see comment]. Eur Addict Res 1999;5:36-42.
5. Haeckel R. Factors influencing the saliva/plasma ratio of drugs. Ann NY Acad Sci 1993;694:128-42.
6. Jenkins AJ, Oyler JM, Cone EJ. Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. J Anal Toxicol 1995;19:359-74.
7. Silber BY, Papafotiou K, Croft RJ, Ogden E, Swann P, Stough C. The effects of dexamphetamine on simulated driving performance. Psychopharmacology (Berl) 2005; 179:536-43.
8. Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eu J Drug Metabol Pharmacokinet 1991;16:249-55.
9. Clarke J, Wilson JF. Proficiency testing (external quality assessment) of drug detection in oral fluid. Forensic Sci Int 2005;150:161-4. [10] Committee CH-039. Procedures for specimen collection and the detection and quantitation of drugs in oral fluid. In: Council of Standards Australia, ed. Australian Standard. Sydney, NSW: Standards Australia, 2006:32. [11] Drummer OH. Pharmacokinetics of illicit drugs in oral fluid [Review]. Forensic Sci Int 2005;150:133-42.
10. Laloup M, Del Mar Ramirez Fernandez M, Wood M, De Boeck G, Maes V, Samyn N. Correlation of Delta9-tetrahydrocannabinol concentrations determined by LC-MS-MS in oral fluid and plasma from impaired drivers and evaluation of the on-site Drager Drug Test. Forensic Sci Int 2006;161:175-9.
11. Schramm W, Smith RH, Craig PA. Methods of simplified saliva collection for the measurement of drugs of abuse, therapeutic drugs, and other molecules. Ann NY Acad Sci 1993;694:311-13.
12. Moolchan ET, Umbricht A, Epstein D. Therapeutic drug monitoring in methadone maintenance: choosing a matrix. J Addict Dis 2001;20:55-73.
13. Wolff K, Farrell M, Marsden J, et al. Review of biological indicators of illicit drug use, practical considerations and clinical usefulness. Addiction 1999;94:1279-98.
14. Walsh JM, Flegel R, Crouch DJ, Cangianelli L, Baudys J. An evaluation of rapid point-of-collection oral fluid drug-testing devices [see comment]. J Anal Toxicol 2003; 27:429-39.
15. Dyer KR, Wilkinson C, Taylor H, et al. Saliva as a biological matrix for the assessment of drugs of abuse: preliminary results of an evaluation of saliva drug screening technologies within a drug-dependent population. In: DAO ed. Monograph. Perth: Next Step Specialist Drug and Alcohol Services, 2004.
16. Walsh JM, Crouch DJ, Danaceau JP, Cangianelli L, Liddicoat L, Adkins R. Evaluation of ten oral fluid point-of-collection drug-testing devices. J Anal Toxicol 2007; 31:44-54.
17. Cone EJ. Testing human hair for drugs of abuse. I. Individual dose and time profiles of morphine and codeine in plasma, saliva, urine, and beard compared to drug-induced effects on pupils and behaviour. J Anal Toxicol 1990;14:1-7.
18. Cone EJ, Oyler J, Darwin WD. Cocaine disposition in saliva following intravenous, intranasal, and smoked administration. J Anal Toxicol 1997;21:465-75.
19. Cone EJ, Presley L, Lehrer M, et al. Oral fluid testing for drugs of abuse: positive prevalence rates by Intercept immunoassay screening and GC-MS-MS confirmation and suggested cutoff concentrations [see comment]. J Anal Toxicol 2002;26:541-6.
20. Jehanli A, Brannan S, Moore L, Spiehler VR. Blind trials of an onsite saliva drug test for marijuana and opiates. J Forensic Sci 2001;46:1214-20.
21. Kadehjian LJ. Performance of five non-instrumented urine drug-testing devices with challenging near-cutoff specimens. J Anal Toxicol 2001;25:670-9.
22. Menkes DB, Howard RC, Spears GF, Cairns ER. Salivary THC following cannabis smoking correlates with subjective intoxication and heart rate. Psychopharmacology 1991;103: 277-9.
23. Moeller MR, Kraemer T. Drugs of abuse monitoring in blood for control of driving under the influence of drugs. Ther Drug Monit 2002;24:210-21.
24. Niedbala RS, Kardos K, Waga J, et al. Laboratory analysis of remotely collected oral fluid specimens for opiates by immunoassay. J Anal Toxicol 2001;25:310-15.
25. Niedbala RS, Kardos KW, Fritch DF, et al. Detection of marijuana use by oral fluid and urine analysis following single-dose administration of smoked and oral marijuana. J Anal Toxicol 2001;25:289-303.
26. Niedbala RS, Kardos KW, Fritch DF, et al. Passive cannabis smoke exposure and oral fluid testing. II. Two studies of extreme cannabis smoke exposure in a motor vehicle. J Anal Toxicol 2005;29:607-15.
27. Samyn N, De Boeck G, Verstraete AG. The use of oral fluid and sweat wipes for the detection of drugs of abuse in drivers. J Forensic Sci 2002;47:1380-7.
28. Samyn N, De Boeck G, Wood M, et al. Plasma, oral fluid and sweat wipe ecstasy concentrations in controlled and real life conditions. Forensic Sei Int 2002;128:907.
29. Schepers RJ, Oyler JM, Joseph RE Jr, Cone EJ, Moolchan ET, Huestis MA. Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. Clin Chem 2003;49:121-32.
30. Choo RE, Huestis MA. Oral fluid as a diagnostic tool. Clin Chem Lab Med 2004;42:1273-87.
31. Drummer OH. Drug testing in oral fluid. Clin Biochem Rev 2006;27:147-59.
32. Kadehjian L. Legal issues in oral fluid testing. Forensic Sci Int 2005;150:151-60.
33. Siegel IA. The role of saliva in drug monitoring. Ann NY Acad Sci USA 1993;694:86-90.
34. Drummer OH, Gerostamoulos D, Chu M, Swann P, Boorman M, Cairns I. Drugs in oral fluid in randomly selected drivers. Forensic Sci Int 2007;170:105-10.
35. Wong RC, Tran M, Tung JK. Oral fluid drug tests: effects of adulterants and foodstuffs. Forensic Sci Int 2005; 150:175-80.
36. Navarro M, Pichini S, Farre M, et al. Usefulness of saliva for measurement of 3,4-methylenedioxymethamphetamine and its metabolites: correlation with plasma drug concentrations and effect of salivary pH. Clin Chem 2001;47:1788-95.
37. Aps JK, Martens LC. The physiology of saliva and transfer of drugs into saliva [Review], Forensic Sci Int 2005; 150:119-31.
38. Streckfus CF, Bigler LR. Saliva as a diagnostic fluid. Oral Dis 2002;8:69-76.
39. Kidwell DA, Holland JC, Athanaselis S. Testing for drugs of abuse in saliva and sweat [erratum appears in J Chromatogr B Biomed Sci Appl 1999 Jan 22;721(2):333].
40. J Chromatogr B Biomed Sci Appl 1998;713:111-35.
41. Edgar WM. Saliva: its secretion, composition and functions. Bt Dental J 1992;172:305-12.
42. Rasmussen F. Salivary excretion of sulphonamides and barbiturates by cows and goats. Acta Pharmacol Toxicol (Copenh) 1964;21:11-19.
43. Huestis MA, Cone EJ. Relationship of Delta 9-tetrahydro-cannabinol concentrations in oral fluid and plasma after controlled administration of smoked cannabis. J Anal Toxicol 2004;28:394-9.
44. London JA, Battistella FD. Testing for substance use in trauma patients: are we doing enough? Arch Surg 2007; 142:633-8.
45. Reinhard M, Hinkin C, Barclay T, et al. Discrepancies between self-report and objective measures for stimulant drug use in HIV: cognitive, medication adherence and psychological correlates. Addict Behav 2007;32:2727-36.
46. O'Halloran S, Lam V, Dyer KR, Taylor H, Ilett K. Development of a GC-MS method for confirmation of methamphetamine in oral fluid and its use in assessment of the performance of an on-site saliva immunoassay testing system. Ther Drug Monit 2005;27:225.
47. Hold KM, de Boer D, Zuidema J, Maes RA. Saliva as an analytical tool in toxicology. Int J Drug Test 1995;1:1-36.
48. Mucklow JC, Bending MR, Kahn GC, Dollery CT. Drug concentration in saliva. Clin Pharmacol Ther 1978; 24:563-70.
49. Horning MG, Brown L, Nowlin J, Lertratanangkoon K, Kellaway P, Zion TE. Use of saliva in therapeutic drug monitoring. Clin Chem 1977;23:157-64.
50. Wilkinson C, Dyer KR, Mitchell T, Ilett K, Wolff K. A novel matrix for therapeutic drug monitoring in methadone maintenance patients: are oral fluid methadone levels useful? Ther Drug Monit 2007;29:481-2.
51. O'Neal CL, Crouch DJ, Rollins DE, Fatah A, Cheever ML. Correlation of saliva codeine concentrations with plasma concentrations after oral codeine administration. J Anal Toxicol 1999;23:452-9.
52. Tobin G, Giglio D, Gotrick B. Studies of muscarinic receptor subtypes in salivary gland function in anaesthetized rats. Autonom Neurosci Basic Clin 2002;100:1-9.
53. Peek-Asa C. The effect of random alcohol screening in reducing motor vehicle crash injuries. Am J Prev Med 1999;16:57-67.
54. Miller T, Blewden M, Zhang JF. Cost savings from a sustained compulsory breath testing and media campaign in New Zealand. Accid Anal Prev 2004;36:783-94.
55. Loxley W, Lo SK, Homel R, Berger DE, Snortum JR. Young people, alcohol, and driving in two Australian states. Int J Addict 1992;27:1119-29.
56. Robertson MD, Drummer OH. Responsibility analysis: a methodology to study the effects of drugs in driving. Accid Anal Prev 1994;26:243-7.
57. Drummer OH, Gerostamoulos J, Batziris H, et al. The incidence of drugs in drivers killed in Australian road traffic crashes. Forensic Sci Int 2003;134:154-62.
58. Christophersen AS, Morland J. Drugged driving, a review based on the experience in Norway. Drug Alcohol Depend 1997;47:125-35.
59. Davey J, Leal N, Freeman J. Screening for drugs in oral fluid: illicit drug use and drug driving in a sample of Queensland motorists. Drug Alcohol Rev 2007;26:301-7.
60. Verstraete AG, Raes E. Rosita-2 project: final report. Ghent, Belgium: Ghent University, 2006.
61. White T. Drug testing at work: issues and perspectives. Subst Use Misuse 2003;38:1891-902.
62. Roche A. Drugs and the Australian workforce. Of Subst 2007;5:18-19.
63. Bull D. Workplace alcohol and other drug issues: the role of the AOD sector. Of Subst 2007;5:20-1.
64. Allsop S, Phillips M. Drug testing in the workplace: an unfortunate marriage. Paper presented at the 'Under the influence: the issues and practicalities of alcohol and other drug testing in the workplace', Perth, 1996.
65. McCunney R. Drug testing: technical complications of a complex social issue. Am J Indust Med 1989;15:589-600.
66. Schottenfeld RS. Drug and alcohol testing in the work-place-objectives, pitfalls, and guidelines. Am J Drug Alcohol Abuse 1989;15:413-27.